Dozens of people have filed lawsuits in the United States against GLP-1 companies, which make popular weight-loss drugs like Ozempic and Mounjaro, claiming their products caused a rare condition that can cause permanent vision loss, US media outlets report. The cases and alleged risk could present a significant challenge to a fledgling industry that analysts expected to generate about $100bn in annual sales in the next 10 years after being taken by millions of people in the US and making inroads into combatting widespread obesity in the country.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.